Epelsiban
Epelsiban (INN, USAN, code name GSK-557,296-B) is an orally bioavailable drug which acts as a selective and potent oxytocin receptor antagonist (Ki = 0.13 nM). It was initially developed by GlaxoSmithKline (GSK) for the treatment of premature ejaculation in men and then as an agent to enhance embryo or blastocyst implantation in women undergoing embryo or blastocyst transfer associated with in vitro fertilization (IVF)., and was also investigated for use in the treatment of adenomyosis.
primaryTopic
Epelsiban
Epelsiban (INN, USAN, code name GSK-557,296-B) is an orally bioavailable drug which acts as a selective and potent oxytocin receptor antagonist (Ki = 0.13 nM). It was initially developed by GlaxoSmithKline (GSK) for the treatment of premature ejaculation in men and then as an agent to enhance embryo or blastocyst implantation in women undergoing embryo or blastocyst transfer associated with in vitro fertilization (IVF)., and was also investigated for use in the treatment of adenomyosis.
has abstract
Epelsiban (INN, USAN, code nam ...... the treatment of adenomyosis.
@en
CAS number
1159097-48-9 (besylate)
872599-83-2
ChEMBL
DrugBank
FDA UNII code
T2EZ19HX73
KEGG
PubChem
Wikipage page ID
33,556,050
page length (characters) of wiki page
Wikipage revision ID
1,000,272,758
Link from a Wikipage to another Wikipage
ATC prefix
None
@en
CAS number
CAS supplemental
ChEMBL
ChemSpiderID
DrugBank
DB11934
@en
IUPAC name
KEGG
D10117
@en
legal status
Non-regulated
@en
PubChem
11,634,973
SMILES
CC[C@H][C@@H]1CN[C@@H]C4CC5=CC=CC=C5C4
@en
StdInChIKey
UWHCWRQFNKUYCG-QUZACWSFSA-N
@en
UNII
T2EZ19HX73
@en
wikiPageUsesTemplate
hypernym
comment
Epelsiban (INN, USAN, code nam ...... the treatment of adenomyosis.
@en
label
Epelsiban
@en